Euro vs US Dollar

Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

Registrieren

CANF

Can Fite BioPharma (CANF)

Can Fite BioPharma Ltd

Von:

Regulatory News

Text Search:

Sortieren nach:

Non-Regulatory News

Showing the most relevant articles for your search:AMEX:CANF

1 2 3 4 5 6 7 8 9 10 Next >>

Datum	Zeit	Quelle	Überschrift	Symbol	Firma
25/04/2024	13h00	Business Wire	Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal	AMEX:CANF	Can Fite BioPharma Ltd
15/04/2024	13h00	Business Wire	Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH	AMEX:CANF	Can Fite BioPharma Ltd
03/04/2024	13h00	Business Wire	Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients	AMEX:CANF	Can Fite BioPharma Ltd
28/03/2024	12h00	Business Wire	Can-Fite Reports 2023 Financial Results and Clinical Update	AMEX:CANF	Can Fite BioPharma Ltd
11/03/2024	12h27	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
11/03/2024	12h00	Business Wire	Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference	AMEX:CANF	Can Fite BioPharma Ltd
28/02/2024	13h06	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
28/02/2024	13h00	Business Wire	Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada	AMEX:CANF	Can Fite BioPharma Ltd
14/02/2024	21h32	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	AMEX:CANF	Can Fite BioPharma Ltd
30/01/2024	13h24	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
30/01/2024	13h00	Business Wire	Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication	AMEX:CANF	Can Fite BioPharma Ltd
29/01/2024	13h05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
29/01/2024	13h00	Business Wire	Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study	AMEX:CANF	Can Fite BioPharma Ltd
08/01/2024	06h15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	AMEX:CANF	Can Fite BioPharma Ltd
28/12/2023	22h16	Edgar (US Regulatory)	Form F-3/A - Registration statement by foreign private issuers: [Amend]	AMEX:CANF	Can Fite BioPharma Ltd
20/12/2023	13h09	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
20/12/2023	13h00	Business Wire	The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies	AMEX:CANF	Can Fite BioPharma Ltd
18/12/2023	13h07	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
18/12/2023	13h00	Business Wire	Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan	AMEX:CANF	Can Fite BioPharma Ltd
12/12/2023	22h15	Edgar (US Regulatory)	Form F-3 - Registration statement by foreign private issuers	AMEX:CANF	Can Fite BioPharma Ltd
04/12/2023	13h05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
04/12/2023	13h00	Business Wire	Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development	AMEX:CANF	Can Fite BioPharma Ltd
30/11/2023	13h05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
30/11/2023	13h00	Business Wire	Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update	AMEX:CANF	Can Fite BioPharma Ltd
22/11/2023	22h20	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	AMEX:CANF	Can Fite BioPharma Ltd
22/11/2023	22h15	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
21/11/2023	22h30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
21/11/2023	19h53	GlobeNewswire Inc.	Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds	AMEX:CANF	Can Fite BioPharma Ltd
21/11/2023	13h03	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
21/11/2023	13h00	Business Wire	Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson	AMEX:CANF	Can Fite BioPharma Ltd

Showing the most relevant articles for your search:AMEX:CANF

1 2 3 4 5 6 7 8 9 10 Next >>

Gold vs US Dollar

Deutsche Telekom (QX)

Euro vs Sterling

Health Care Select Sector

Deutsche Lufthansa

JP Morgan Chase

Deutsche Telekom

Invesco QQQ Trust Series 1

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen